USP7 and cancer: In this regard, harnessing the notion that USP7 inhibitors, several of which display efficacy for cancer therapy in preclinical studies52, potently deplete TOPORS and recapitulate the consequences of TOPORS loss due to a critical role of USP7 in antagonizing TOPORS auto-ubiquitylation and preventing its proteasomal degradation may be particularly useful.